188 related articles for article (PubMed ID: 19526626)
1. The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Yood MU; DeLorenze G; Quesenberry CP; Oliveria SA; Tsai AL; Willey VJ; McQuade R; Newcomer J; L'Italien G
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):791-9. PubMed ID: 19526626
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
5. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
9. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
10. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Park Y; Hernandez-Diaz S; Bateman BT; Cohen JM; Desai RJ; Patorno E; Glynn RJ; Cohen LS; Mogun H; Huybrechts KF
Am J Psychiatry; 2018 Jun; 175(6):564-574. PubMed ID: 29730938
[TBL] [Abstract][Full Text] [Related]
11. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Citrome L; Volavka J
Postgrad Med; 2004 Oct; 116(4):49-51, 55-9, 63. PubMed ID: 15510593
[TBL] [Abstract][Full Text] [Related]
12. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Dubois D
Curr Opin Pediatr; 2005 Apr; 17(2):227-33. PubMed ID: 15800418
[TBL] [Abstract][Full Text] [Related]
13. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
[TBL] [Abstract][Full Text] [Related]
14. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics.
Citrome L; Collins JM; Nordstrom BL; Rosen EJ; Baker R; Nadkarni A; Kalsekar I
J Clin Psychiatry; 2013 Dec; 74(12):1199-206. PubMed ID: 24434088
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
16. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
17. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Miller EA; Leslie DL; Rosenheck RA
J Nerv Ment Dis; 2005 Jun; 193(6):387-95. PubMed ID: 15920379
[TBL] [Abstract][Full Text] [Related]
18. The case for atypical antipsychotics in bipolar disorder.
Shattell M; Keltner NL
Perspect Psychiatr Care; 2004; 40(1):34-8. PubMed ID: 15147051
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Pathak P; West D; Martin BC; Helm ME; Henderson C
Psychiatr Serv; 2010 Feb; 61(2):123-9. PubMed ID: 20123816
[TBL] [Abstract][Full Text] [Related]
20. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
